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Abstract 
Purpose: To investigate the dose–response relationship of green tea polyphenol in an animal model of 
lung cancer. 
Methods: The effects of epigallocatechin-3-gallate (EGCG) on the inhibition of xenograft tumor growth, 
the accumulation of 8-hydroxy-2'-deoxyguanosine (8-OHdG), and apoptosis based on 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay were evaluated in non-small cell lung 
cancer (NSCLC) cell lines, namely, H1155, H661, and A427 (a human lung carcinoma-derived cell line). 
The dose-dependent effects of EGCG on H1155 xenograft tumor growth, as well as the levels of EGCG 
in plasma and tissue, were also determined in male nude mice. 
Results: EGCG inhibited the growth of NSCLC-derived cell lines (H1155) over a 45-day period. There 
was a significant reduction (57 %) in tumor weight in EGCG-fed (0.5 %) animals compared with the 
control group (p < 0.05). Linear regression analysis revealed a dose-dependent reduction in tumor size. 
MTT assay results revealed inhibition of H1155 cell growth (25 %, p < 0.05) after 24 h treatment with 
EGCG. The addition of superoxide dismutase (5 U/mL) and catalase (30 U/mL) reduced the inhibitory 
effect of EGCG. Mice administered 30 mg/kg EGCG via intraperitoneal injection exhibited the least 
amount of oxidative stress. 
Conclusion: The results demonstrate the concentration-dependent inhibitory effects of EGCG on lung 
cancer cells, including H1155 cells, both in vitro and in vivo. The induction of reactive oxygen species, 
oxidative DNA damage, and apoptosis were evident following EGCG treatment.  
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Following water, tea is the most widely 
consumed drink throughout the world. Leaves of 
the Camellia sinensis plant (either cured or 
green) are used to make the beverage. The 
leaves of C. sinensis are rich in polyphenols 
commonly referred to as catechins, which are 
composed of (−)-epigallocatechin-3-gallate 
(EGCG), (−)-epicatechin-3-gallate, (−)-epigallo-
catechin, and (−)-epicatechin.  
 
EGCG is the most abundant polyphenol in tea. 
The anti-cancer properties of green tea 
polyphenols have already been described 
elsewhere. However, its dose–response 
relationship has not been established in an 
animal model [1,2]. A low dose of EGCG (0.04 
%) inhibits tumors in experimental models [3,4]. 
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However, few studies have demonstrated the 
efficacy of green tea polyphenols at much higher 
concentrations (e.g., 0.3 %) [5,6]. Tumor 
inhibition was also observed following 
intraperitoneal (i.p.) injection of EGCG [7,8]. A 
concentration of 4 – 150 µM EGCG is used in 
most in vitro experiments; however, the 
bioavailability of EGCG is less than 0.5 µM [9]. 
Several studies have noted a lack of 
understanding the correlation between the dose–
response and anti-tumor activity in vivo; an 
obvious gap in the relationship between dose 
and metabolism has also attracted much criticism 
[1,10]. 
 
Reactive oxygen species (ROS) are the most 
common causative factor of cell stress and DNA 
damage [11]. Evaluation of the DNA oxidative 
product 8-hydroxy-2′-deoxyguanosine (8-OHdG) 
is useful for studying ROS-mediated oxidative 
stress [12–14]. Rad3-related kinase and mutated 
ataxia-telangiectasia can also be used as 
markers of DNA damage [15,16]. The present 
study aimed to identify the dose–response 
relationship of EGCG in human lung cancer 






Non-small cell lung cancer (NSCLC) cell lines 
H1155, H661, and A427 (a human lung 
carcinoma-derived cell line), the human 
colorectal adenocarcinoma cell line SW1417, 
and mouse-derived lung adenocarcinoma LA-4 
cells were obtained from the American Type 
Culture Collection (ATCC; Manassas, VA, USA). 
H1155, H661, and LA-4 cells were maintained in 
Roswell Park Memorial Institute (RPMI)-1640 
medium; A427 cells were maintained in F-12K 
medium supplemented with 10 % fetal bovine 
serum (FBS). SW1417 cells were maintained in 
L15 medium supplemented with 2 mM glutamine 
and 10 % FBS. Cells were cultured under 
standard culture conditions of 37 °C and 5 % 
CO2. Milli-Q® water was used to dissolve EGCG, 
and a concentration range of 5 – 50 μM EGCG 
was used. 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), superoxide 
dismutase (SOD), and catalase assays were 
performed using commercially available kits from 
Cayman Chemicals (Ann Arbor, Michigan, USA) 
according to the manufacturer’s protocols. 
 
In vivo experiments 
 
All animal procedures were performed according 
to the guidelines of the Care and Use of 
Laboratory Animals and were approved by the 
Animal Ethical Care and Use Committee of Anhui 
Medical University, China (Ethical Permit 
04/S0356/728). All experimental procedures 
were conducted in compliance with institutional 
guidelines and conformed to the National 
Research Council Guide for the Care and Use of 
Laboratory Animals [17]. Male nude mice were 
purchased from Sino-British Lab Animal Ltd. 
(Shanghai, China) and were fed an AIN93M diet 
(Keaoxieli Diet Co., Beijing, China). Mice were 
divided into four groups with 12 mice per group. 
Six-week-old mice were injected with H1155 cells 
(1 × 106 cells) subcutaneously (s.c.) in both 
flanks. Each group received different 
concentrations of EGCG. Two groups received 
oral administration of EGCG (0.1 and 0.5 %), 
while one group received 30 mg/kg EGCG 
administered via intraperitoneal (i.p.) injection; 
the fourth group served as a control group (no 
EGCG administered). Each animal was 
monitored for tumor size and body weight. After 
45 d of treatment, all mice were sacrificed via 
euthanasia by CO2 asphyxiation. The tumor 
tissue was resected and used for biological 
analysis. 
 
Plasma and tissue levels of EGCG 
 
Tissue samples were analyzed according to a 
procedure described by Lee et al [16]. Briefly, 0.1 
g of tissue was homogenized in 0.05 mL of 1 % 
ethyl acetate and 0.45 mM ascorbic acid in 
methanol. After centrifugation, 500 μL of the 
supernatant was extracted twice with 1 mL 
hexane. After the second extraction, samples 
were mixed with 10 μL of 0.2 % ascorbic acid 
and dried. Dried samples were reconstituted in 
100 μL of 10 % aqueous acetonitrile. Fifty 
microliters of sample were then injected into a 
high-performance liquid chromatography (HPLC) 
system. Results are expressed as µmol/kg on 




Excised tumor tissues from nude mice were fixed 
in paraformaldehyde for 24 h and embedded in 
paraffin. Sections (4 µm) of the paraffin-
embedded tissues were examined on poly-
lysine-coated slides. Slides were rinsed twice in 
300 mL phosphate-buffered saline (PBS) and 
blocked at room temperature for 1 h. Slides were 
then incubated with the appropriate primary 
antibody (in antibody dilution buffer) and 
incubated in a humidified chamber at room 
temperature for 1 h. After washing with PBS, 
slides were incubated with the appropriate 
secondary antibody. Sections were 
counterstained with hematoxylin and observed 
under a light microscope (Nikon, Shinagawa, 
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Tokyo, Japan). Images were quantified using 
ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). 
 
Analysis of apoptotic cells 
 
After treatment with EGCG, H1155 cells were 
harvested by trypsinization. For staining, 2 – 5 × 
105 cells (per mL) were resuspended in 500 μL 
HEPES N-[2-hydroxyethyl] piperazine-N'-[2-
ethanesulphonic acid]-buffered saline (pH 7.4). 
The cell suspension (190 μL) was added to 10 
μL annexin V-fluorescein isothiocyanate 
(Invitrogen Molecular Probes, South San 
Francisco, CA, USA), mixed gently, and 
incubated at room temperature for 15 min. Cells 
were centrifuged and propidium iodide buffer (1 
μg/mL) was added. A 488-nm laser coupled to a 
cell sorter (Cytomics® FC500; Beckman Coulter 





Results are presented as the mean ± standard 
deviation (SD). The Kruskal–Wallis test (one-way 
analysis of variance [ANOVA] on ranks) was 
used for statistical analysis. A P value < 0.05 
was considered to indicate a statistically 
significant difference. Spearman's rank 
correlation was used to determine the degree of 
association between continuous variables. SPSS 
(version 11.5; SPSS Inc., Chicago, IL, USA) was 




Dose–response inhibition of H1155 xenograft 
tumor growth by EGCG 
 
There were no changes in body weight gain or 
food intake among any of the five animal cohorts. 
EGCG inhibited the growth of the NSCLC-
derived cell line (H1155) over 45 d (Figure 1). 
There was a significant reduction (57 %) in tumor 
weight in EGCG-fed animals (0.5 %) compared 
with the control group (p < 0.05). Linear 
regression analysis revealed that the reduction in 
tumor weight correlated in a dose-dependent 
fashion (y  =  0.945 − 1.027x, R2 = 0.97; where y 
= tumor weight (g) and x is the % EGCG content 
administered orally). In addition, the i.p. 
administration of EGCG (30 mg/kg) resulted in 
significant inhibition (69 %). 
 
EGCG concentration in biological samples 
 
A dose-dependent increase in EGCG 
concentration was observed in the blood and 
xenograft tumors after oral administration of 
EGCG (0.1 or 0.5 %). The increase in EGCG 
was much higher via the i.p. route (30 mg/kg 
EGCG). The mean plasma EGCG levels were 
0.02, 0.25, 0.51, and 3 μmol/L in control, 0.1 and 
0.5 % EGCG (oral), and 30 mg/kg EGCG (i.p.) 
animals, respectively (Figure 2A). The mean 
EGCG concentrations in xenograft tumors were 
0.045, 0.15, 0.19, and 0.4 μmol/kg in control, 0.1 
and 0.5 % EGCG (oral), and 30 mg/kg EGCG 
(i.p.) animals, respectively (Figure 2B).  
 
Figure 1: Inhibition of H1155 lung cancer xenografts after treatment with EGCG. (A) Time versus mean tumor 
volume. (B) Effect of EGCG on tumor weight. Values are presented as the mean ± standard error (SE). A P value 
less than 0.05 was considered significant 
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Figure 2: (A) EGCG levels in plasma and (B) tumors. Values are presented as mean ± SE; * indicates 
a significant value 
 
It was previously reported that EGCG appears at 
0.5 of 3 – 4 h and takes 90 – 120 min to reach 
peak plasma levels (4, 12). In our study, the 
plasma levels achieved may represent only half 
of the peak plasma levels since blood was 
collected in the morning and feeding mostly 
occurred at night. The IC50 value calculated by 
the regression analysis was 0.15 µmol/kg. The 
plasma EGCG level was 5-fold higher in animals 
administered EGCG via i.p. injection than the 
oral route. 
 
Evaluation of oxidative stress parameters in 
xenograft tumors 
 
DNA damage due to oxidative stress was 
investigated by immunohistochemical analysis of 
the accumulation of 8-OHdG. Positive-control 
tissue was treated with H2O2. The treatment 
group consisted of animals administered 0.1 and 
0.5 % EGCG orally and 30 mg/kg EGCG via i.p. 
injection. As expected, a greater accumulation of 
8-OHdG was observed in the positive control. An 
increase in 8-OHdG expression was also 
observed in EGCG-treated animals. Animals 
administered 30 mg/kg EGCG via i.p. injection 
showed the least amount of oxidative stress 
(Figure 3A). 
 
Cancer inhibitory effect of EGCG 
 
The inhibitory effect of EGCG was evaluated by 
the MTT assay, which showed that EGCG 
inhibited H1155 cells after treatment for 24 h. 
The number of apoptotic cells increased in a 
concentration-dependent manner (Figure 4). The 
presence of SOD (5 U/mL) and catalase (30 
U/mL) reduced the inhibitory action of EGCG. 
Similar results were obtained when the same 
experiment was repeated in different cell lines. 
A437 and SW1417 cells showed the weakest 
response to EGCG treatment. These results 
support the hypothesis that the inhibitory effect of 




The present study demonstrates that EGCG 
exhibits significant concentration-
dependent inhibitory effects against the growth of 
lung cancer H1155 cells in tumor xenografts as 
well as in culture. Furthermore, EGCG markedly 
increased the levels of ROS in a concentration- 
and time-dependent manner both in vitro and in 
vivo. Moreover, our current findings reveal that 
EGCG activates the generation of ROS, leading 
to oxidative DNA damage in H1155 cells and in a 
tumor xenograft model. 
 
Previous studies have suggested several 
mechanisms of action for the inhibitory effects of 
EGCG on cancer cell growth and development. 
However, various experiments have proposed 
only two anti-cancer mechanisms of EGCG. The 
first involves the interaction between EGCG and 
specific proteins wherein EGCG binds to target 
proteins and consequently modulates gene 
expression and signaling pathways associated 
with carcinogenesis, either directly or indirectly. 
 
Many EGCG target proteins have been identified, 
including vimentin [17], HIF-1α, FYN (FYN Proto-
Oncogene, Src Family Tyrosine Kinase) [18], 
laminin receptor [19], and insulin-like growth 
factor 1 receptor [4,20], 
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Figure 3: (A) Photomicrographs representing the effects of EGCG and 8-hydroxy-2'-deoxyguanosine (8-OHdG) 
accumulation in xenograft tissues. (B) Percentage of 8-OHdG-positive cells. (C) Apoptotic index in different 
treatment groups. Values are presented as mean ± SE 
 
 
Figure 4: Inhibitory effect of EGCG in different cell lines. (A) Percentage of viable CL13 cells. (B) Percentage of 
viable H460 cells. (C) Percentage of viable HT29 cells. (D) Percentage of viable A549 cells. (E) Percentage of 
viable H1299 cells. Values are presented as mean ± standard deviation (SD)
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that exhibit increased binding affinity towards 
EGCG. The second mechanism of action of 
EGCG includes the increased production of 
ROS, which leads to apoptosis and damage to 
cancer cells. We demonstrated this mechanism 
in the present study in the experimental cell line, 
wherein EGCG induced a concentration-
dependent growth reduction of H1155 lung 
cancer cells. The growth of H1155 lung cancer 
cells was reduced in a concentration-dependent 
manner, with an estimated IC50 value of 20 μM. 
This inhibition of viable H1155 cells was 
observed due to ROS-activated apoptosis via 
EGCG. Additionally, most of the ROS produced 
were blocked by the addition of SOD and 
catalase. These results are similar to the report 
in which EGCG-induced apoptosis was inhibited 
by catalase in lung cancer H661 cells [20]. 
 
The present study aimed to investigate the 
concentration-dependent anti-carcinogenic 
effects of EGCG on H1155 lung cancer cells, 
including the involvement of oxidative stress in a 
tumor xenograft animal model and in culture. In 
this study, treatment with EGCG resulted in a 
concentration-dependent inhibition of the growth 
of H1155 lung cancer cells in tumor xenografts 
and in culture. The dose of EGCG correlated with 
the inhibition of cancer cell growth, as shown by 
linear regression analysis. Furthermore, an 
estimated IC50 value of 0.15 μM in vivo is much 
lower than the IC50 value of 20 μM in vitro (Figure 
4), indicating that the effective concentration of 
EGCG was much higher in culture (in vitro) 
compared with the dose in the animal model (in 
vivo) [21].  
 
Many studies support that EGCG exhibits greater 
inhibitory effects against cancer cell growth in 
vitro compared with in vivo. Nevertheless, both in 
vitro and in vivo systems differ and thus 
comparative results could be equivocal. 
Therefore, linear regression analysis was used to 
compare the results of in vitro and in vivo 
studies. A remarkable difference in the effective 
inhibitory concentration of EGCG was observed 
in the xenograft animal model, which may be due 
to long-term exposure to EGCG in the xenograft 
animal study versus short-term exposure to 
EGCG in vitro. Moreover, previous research 
demonstrated that a longer treatment duration 
can decrease the effective EGCG concentration 
in culture [22]. 
 
Environmental conditions used in cell culture are 
unlike those in a xenograft animal model. EGCG 
degradation likely results in ROS generation 
outside of cells in culture, leading to apoptosis, 
whereas ROS is mostly generated inside of cells 
in a xenograft model. Furthermore, our results 
demonstrated that intracellular ROS induced 
following EGCG treatment were attenuated by 
the addition of SOD and catalase in H1155 cells. 
SOD and catalase remarkably attenuated the 
ROS produced following treatment with EGCG 
(50 μM) for 24 h. However, considerable levels of 
ROS remained because of the presence of 
intracellular ROS inside of the cells. N-acetyl-
cysteine (NAC), an antioxidant, decreased ROS 
production to control levels both extracellularly 
and intracellularly. These results demonstrate the 
similar effects of the EGCG-induced generation 
of mitochondrial ROS and changes in 
mitochondrial membrane potential. 
 
We observed an association between oxidative 
stress and DNA damage in EGCG-induced 
apoptosis in the xenograft tumor, which was 
demonstrated by the concentration-dependent 
generation of 8-OHdG following EGCG 
treatment. The induction of oxidative stress in 
tumors by EGCG is possible due to the presence 
of the transcription factor NF-E2-related factor-2 
and hemeoxygenase-1, which control the 
expression of various antioxidants and 
detoxification of enzymes [23,24]. However, the 
effects of NF-E2-related factor-2 and 
hemeoxygenase-1 are comparatively greater in 
SW1417 and A427 cells, which exhibited a 





The findings of the present study demonstrate 
the concentration-dependent inhibitory effects of 
EGCG on lung cancer cells (H1155 cells) both in 
vitro and in vivo. EGCG induces ROS, and its 
involvement in apoptosis, as well as oxidative 
DNA damage, has been established.  This study 
supports the use of green tea as a 
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